H.C. Wainwright raises Rhythm Pharmaceuticals stock price target to $130 on Japan approval
H.C. Wainwright raised its price target for Rhythm Pharmaceuticals (RYTM) to $130 from $105, maintaining a Buy rating. The stock trades at $90.78, with analysts' targets ranging from $105 to $160. Japan approved IMCIVREE for acquired hypothalamic obesity, supported by Phase 3 trial data. Rhythm reported Q2 2026 earnings, with revenue of $71.26 million, beating estimates. The company is not yet profitable but has 89% gross margins and 54% revenue growth over the last year.
How this was made
The 30-second read
Why it matters
The approval expands Rhythm's addressable market and could drive near‑term share appreciation, especially as the company reports strong Q2 results.
Market read
Regulatory clearance in Japan is a fresh, material catalyst for Rhythm, likely prompting buying interest.
What to watch
Potential pricing negotiations in Japan could affect revenue timing.
Background
Rhythm Pharmaceuticals received its first Japanese approval for IMCIVREE, a setmelanotide therapy for acquired hypothalamic obesity, and analysts raised price targets.
Ticker impact
Japan's health ministry approved Rhythm's drug IMCIVREE, and H.C. Wainwright raised its price target to $130.
likely upside as investors price in Japanese launch potential
Regulatory clearance in a major market is a material catalyst for a biotech with no prior sales there.
Market effects
strengthens the obesity‑treatment niche and may boost peer biotech valuations.
adds a new product to Japan's rare‑disease portfolio.
demonstrates successful international regulatory pathways for US‑listed biotech.
Counterpoint
If Japanese uptake is slow due to prescription renewal rules, the upside may be limited.
Key entities
- companyRhythm Pharmaceuticals
NASDAQ‑listed biotech developing obesity treatments.
- analystH.C. Wainwright
Raised price target to $130.
